Jackson Acquisition Company
RJAC-WT
New York Stock Exchange0.01
USD
- -
- -
Jackson Acquisition Company
RJAC-WT
(New York Stock Exchange)
Recent
price
0.01
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Jackson Acquisition Company (NYSE: RJAC; RJAC-WT) operates as a blank check company whose sole business is to effect a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses, with a primary focus on high-quality targets in the healthcare services, healthcare technology, or broader healthcare industry sectors in the United States; its securities include redeemable warrants (RJAC-WT) exercisable at $11.50 per share for Class A common stock, subject to adjustment and redemption terms. The company holds approximately 22.25 million shares of Class A common stock outstanding, maintains a trust account for public shares with funds deposited from its $200 million initial public offering priced at $10.00 per unit in December 2021, underwritten by BofA Securities, and conducts no other significant operations. Incorporated in Delaware on March 5, 2021, and headquartered at 2655 Northwinds Parkway in Alpharetta, Georgia, it is led by President and CEO Richard L. Jackson, with Chairman John E. "Jeb" Bush and a management team boasting extensive healthcare experience from entities like Jackson Healthcare and CMS. In a major development, Jackson Acquisition Company announced the redemption of all outstanding public shares effective June 13, 2023, after failing to complete an initial business combination within the required timeframe under its charter, ceasing operations except for wind-up activities, with warrants expiring worthless and the NYSE filing to delist securities shortly thereafter; the sponsor waived redemption rights on Class B founder shares, and no merger, acquisition, funding, or strategic shifts have occurred since, positioning RJAC-WT as a residual warrant instrument trading at minimal value amid post-liquidation status.